These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21369702)

  • 1. Clinical significance of circulating galectins as colorectal cancer markers.
    Watanabe M; Takemasa I; Kaneko N; Yokoyama Y; Matsuo E; Iwasa S; Mori M; Matsuura N; Monden M; Nishimura O
    Oncol Rep; 2011 May; 25(5):1217-26. PubMed ID: 21369702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
    Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
    Chen C; Chen LQ; Yang GL; Li Y
    Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
    Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
    Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
    Zhao XW; Jiang B; Han CZ; Jing JX
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of tumor markers and evaluation of their predictive value in patients with colorectal cancer.
    Liu ZP; Li LM; Liu XL; Zhang DX
    Onkologie; 2012; 35(3):108-13. PubMed ID: 22414974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
    Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
    J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
    Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
    Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
    Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
    Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients].
    Grotowski M; Maruszyński M; Piechota W
    Pol Merkur Lekarski; 2001 Dec; 11(66):476-9. PubMed ID: 11899841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
    Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alu-based cell-free DNA: a potential complementary biomarker for diagnosis of colorectal cancer.
    Qi J; Qian C; Shi W; Wu X; Jing R; Zhang L; Wang Z; Ju S
    Clin Biochem; 2013 Jan; 46(1-2):64-9. PubMed ID: 22975639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring.
    Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Liu BY; Zhu ZG
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1913-9. PubMed ID: 16336453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis.
    Mroczko B; Groblewska M; Wereszczyńska-Siemiatkowska U; Okulczyk B; Kedra B; Łaszewicz W; Dabrowski A; Szmitkowski M
    Clin Chim Acta; 2007 May; 380(1-2):208-12. PubMed ID: 17368603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular detection of circulating cancer cells in the peripheral blood of patients with colorectal cancer by using membrane array with a multiple mRNA marker panel.
    Yeh CS; Wang JY; Wu CH; Chong IW; Chung FY; Wang YH; Yu YP; Lin SR
    Int J Oncol; 2006 Feb; 28(2):411-20. PubMed ID: 16391796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor markers in patients with relapse of colorectal carcinoma.
    Lipská L; Visokai V; Levý M; Svobodová S; Kormunda S; Fínek J
    Anticancer Res; 2007; 27(4A):1901-5. PubMed ID: 17649792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokeratin serum biomarkers in patients with colorectal cancer.
    Holdenrieder S; Stieber P; Liska V; Treska V; Topolcan O; Dreslerova J; Matejka VM; Finek J; Holubec L
    Anticancer Res; 2012 May; 32(5):1971-6. PubMed ID: 22593474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients.
    Nakagoe T; Sawai T; Tsuji T; Jibiki MA; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K
    Hepatogastroenterology; 2003; 50(51):696-9. PubMed ID: 12828063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEA in activated macrophages. New diagnostic possibilities for tumor markers in early colorectal cancer.
    Japink D; Leers MP; Sosef MN; Nap M
    Anticancer Res; 2009 Aug; 29(8):3245-51. PubMed ID: 19661342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.